Coronado Biosciences, a New York-based company focused on oncology drug development, has completed a financing series worth $21.6 million. The funds will be used to develop its acute myelogeous leukemia drug, CNDO-109. The company also announced that Glenn Cooper (executive chairman and acting CEO), Eric Rowinsky (vice chairman) and Gary Gemignani (executive VP, COO and CFO) have joined the company. Coronado release